Protocol Ledger

NCT03760003 · Phase II · COMPLETED

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

Interventional Phase II clinical trial protocol NCT03760003 sponsored by Abivax in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-13 Enrollment: 355 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03760003
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)355 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03760003
Protocol FieldVerified Registry Value
NCT IdentifierNCT03760003
Consolidated Lead SponsorAbivax
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment355 participants (ACTUAL)
Registered Start Date2019-08-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03760003
Hospital Research SiteLocationSite Profile
UC San Diego Health and Moores Cancer CenterSan Diego, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI